trazodone has been researched along with Dementia in 32 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia." | 9.08 | A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997) |
| "To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression." | 8.82 | Trazodone for agitation in dementia. ( Fioravanti, M; Grimley, EJ; Martinon-Torres, G, 2004) |
| "In this study of UK population-based electronic health records, we found no association between trazodone use and a reduced risk of dementia compared with other antidepressants." | 7.91 | Trazodone use and risk of dementia: A population-based cohort study. ( Brauer, R; Hayes, JF; Howard, R; Kim, J; Lau, WCY; Man, KKC; Osborn, DPJ; Wong, ICK, 2019) |
| "Trazodone is not a uniformly safer alternative to atypical antipsychotics, given the similar risk of falls and fractures among older adults with dementia." | 7.88 | Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. ( Austin, PC; Bronskill, SE; Gomes, T; Ho, JM; Huang, A; Straus, SE; Watt, JA, 2018) |
| "Pimavanserin is a serotonin 5HT-2A receptor inverse agonist that has recently been shown to reduce psychosis related to dementia." | 5.91 | [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. ( Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023) |
| "Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65." | 5.37 | Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. ( Camargos, EF; Freitas, MP; Lima, Jde O; Medeiros-Souza, P; Miranda, LC; Pandolfi, MB; Pimentel, W; Quintas, JL, 2011) |
| "The authors compared the efficacy and side effects of trazodone and haloperidol for treating agitated behaviors associated with dementia." | 5.08 | A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. ( Berisford, MA; Gray, KF; Gunay, I; Mahler, ME; Sultzer, DL, 1997) |
| " Suvorexant received an approval for the treatment of patients with comorbid insomnia and dementia." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "Randomized, controlled trials of antidepressants (selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, trazodone, and other antidepressants), compared to either placebo or comparator medications (typical or atypical antipsychotics, anticonvulsants, benzodiazepines, cholinesterase inhibitors, memantine or other medications) for treatment of agitation or psychosis in older adults with dementia." | 4.87 | Antidepressants for agitation and psychosis in dementia. ( Adunuri, N; Gill, SS; Gruneir, A; Herrmann, N; Rochon, P; Seitz, DP, 2011) |
| " TRAZODONE: Studies conducted in patients with Alzheimer's disease, mixed type dementia, or fronto-temporal dementia have shown the efficacy of trazodone for diverse types of symptoms: sadness, emotional disorders, irritability, fear, psychomotor instability, delirant ideas." | 4.82 | [Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias]. ( Lebert, F, 2003) |
| "To determine the clinical efficacy and safety of trazodone, for any type of behavioural or psychological cognition in people with dementia without an additional diagnosis of depression." | 4.82 | Trazodone for agitation in dementia. ( Fioravanti, M; Grimley, EJ; Martinon-Torres, G, 2004) |
| " The initiation of antipsychotic and trazodone use was compared by year of admission using discrete time survival analysis and stratified by history of dementia." | 4.31 | Changes in the Initiation of Antipsychotics and Trazodone Over Time: A Cohort Study of New Admissions to Nursing Homes in Ontario, Canada. ( Austin, PC; Bronskill, SE; Guan, J; Harris, DA; Iaboni, A; Maclagan, LC; Maxwell, CJ; Pequeno, P; Rosella, LC, 2023) |
| "In this study of UK population-based electronic health records, we found no association between trazodone use and a reduced risk of dementia compared with other antidepressants." | 3.91 | Trazodone use and risk of dementia: A population-based cohort study. ( Brauer, R; Hayes, JF; Howard, R; Kim, J; Lau, WCY; Man, KKC; Osborn, DPJ; Wong, ICK, 2019) |
| "Trazodone is not a uniformly safer alternative to atypical antipsychotics, given the similar risk of falls and fractures among older adults with dementia." | 3.88 | Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study. ( Austin, PC; Bronskill, SE; Gomes, T; Ho, JM; Huang, A; Straus, SE; Watt, JA, 2018) |
| "Dementia is a global medical and societal challenge; it has devastating personal, social and economic costs, which will increase rapidly as the world's population ages." | 2.82 | Targeting the Unfolded Protein Response as a Disease-Modifying Pathway in Dementia. ( Butcher, AJ; Mallucci, GR; O'Brien, JT; Sidhom, E; Smith, HL; Underwood, BR, 2022) |
| "Pimavanserin is a serotonin 5HT-2A receptor inverse agonist that has recently been shown to reduce psychosis related to dementia." | 1.91 | [Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies]. ( Blanc, F; Javelot, H; Merignac, J; Moog, C; Muller, C; Schorr, B, 2023) |
| "Trazodone is a drug that was introduced in the clinic almost 40 years ago." | 1.48 | Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets. ( Settimo, L; Taylor, D, 2018) |
| "Trazodone was the most commonly used drug among patients (N = 35), with an effectiveness of 65." | 1.37 | Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study. ( Camargos, EF; Freitas, MP; Lima, Jde O; Medeiros-Souza, P; Miranda, LC; Pandolfi, MB; Pimentel, W; Quintas, JL, 2011) |
| " The most commonly administered drug was trazodone at a mean dosage of 70 mg/day (range 50-100 mg/day)." | 1.32 | Pharmacologic management by clinical pharmacists of behavioral and psychological symptoms of dementia in nursing home residents: results from a pilot study. ( Allie, ND; Eng, M; Rojas-Fernandez, CH, 2003) |
| "The pattern of myoclonus is unlike previous reported cases and may relate to activation of serotonin 5HT1A receptors (possibly supersensitive in Pick's disease) or to hypodopaminergia." | 1.29 | Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease. ( Lauterbach, EC, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (15.63) | 18.7374 |
| 1990's | 6 (18.75) | 18.2507 |
| 2000's | 8 (25.00) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 6 (18.75) | 2.80 |
| Authors | Studies |
|---|---|
| Sidhom, E | 2 |
| O'Brien, JT | 2 |
| Butcher, AJ | 1 |
| Smith, HL | 1 |
| Mallucci, GR | 2 |
| Underwood, BR | 2 |
| Padilla, MS | 1 |
| Lewis, J | 1 |
| White, S | 1 |
| Harris, DA | 1 |
| Maclagan, LC | 1 |
| Pequeno, P | 1 |
| Iaboni, A | 1 |
| Austin, PC | 2 |
| Rosella, LC | 1 |
| Guan, J | 1 |
| Maxwell, CJ | 1 |
| Bronskill, SE | 2 |
| Muller, C | 1 |
| Merignac, J | 1 |
| Moog, C | 1 |
| Schorr, B | 1 |
| Javelot, H | 1 |
| Blanc, F | 1 |
| Coin, A | 1 |
| Noale, M | 1 |
| Gareri, P | 1 |
| Trevisan, C | 1 |
| Bellio, A | 1 |
| Fini, F | 1 |
| Abbatecola, AM | 1 |
| Del Signore, S | 1 |
| Malara, A | 1 |
| Mossello, E | 1 |
| Fumagalli, S | 1 |
| Volpato, S | 1 |
| Monzani, F | 1 |
| Bellelli, G | 1 |
| Zia, G | 1 |
| Incalzi, RA | 1 |
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Leng, Y | 1 |
| Diem, SJ | 1 |
| Stone, KL | 1 |
| Yaffe, K | 1 |
| Settimo, L | 1 |
| Taylor, D | 1 |
| Abi-Jaoude, E | 1 |
| Stall, NM | 1 |
| Rochon, PA | 1 |
| Watt, JA | 1 |
| Gomes, T | 1 |
| Huang, A | 1 |
| Ho, JM | 1 |
| Straus, SE | 1 |
| Brauer, R | 1 |
| Lau, WCY | 1 |
| Hayes, JF | 1 |
| Man, KKC | 1 |
| Osborn, DPJ | 1 |
| Howard, R | 1 |
| Kim, J | 1 |
| Wong, ICK | 1 |
| Seitz, DP | 1 |
| Adunuri, N | 1 |
| Gill, SS | 1 |
| Gruneir, A | 1 |
| Herrmann, N | 1 |
| Rochon, P | 1 |
| Camargos, EF | 1 |
| Pandolfi, MB | 1 |
| Freitas, MP | 1 |
| Quintas, JL | 1 |
| Lima, Jde O | 1 |
| Miranda, LC | 1 |
| Pimentel, W | 1 |
| Medeiros-Souza, P | 1 |
| Rojas-Fernandez, CH | 1 |
| Eng, M | 1 |
| Allie, ND | 1 |
| Lebert, F | 2 |
| Stekke, W | 1 |
| Hasenbroekx, C | 1 |
| Pasquier, F | 1 |
| Martinon-Torres, G | 1 |
| Fioravanti, M | 1 |
| Grimley, EJ | 1 |
| Inouye, SK | 1 |
| Kitamura, Y | 1 |
| Kudo, Y | 1 |
| Imamura, T | 1 |
| Le Ber, I | 1 |
| Dubois, B | 1 |
| Klein, DF | 1 |
| Lauterbach, EC | 1 |
| Mintzer, JE | 1 |
| Brawman-Mintzer, O | 1 |
| Tariot, PN | 1 |
| Sultzer, DL | 1 |
| Gray, KF | 1 |
| Gunay, I | 1 |
| Berisford, MA | 1 |
| Mahler, ME | 1 |
| Lawlor, B | 1 |
| Nguyen, M | 1 |
| Myers, WC | 1 |
| Schneider, LS | 1 |
| Sobin, PB | 1 |
| Eimer, M | 1 |
| Simpson, DM | 1 |
| Tingle, D | 1 |
| Wamboldt, MZ | 1 |
| Kalin, NH | 1 |
| Weiler, SJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial To Assess Risk of Delirium in Older Adults Undergoing Hip Fracture Surgery With Spinal or General Anesthesia[NCT02190903] | 15 participants (Actual) | Interventional | 2013-10-31 | Completed | |||
| Evaluation of the CogMe Technology Platform for the Prevention and Early Detection of Delirium Among Older Patients in an Acute Hospital Setting: A Proof of Concept Study[NCT05311761] | 100 participants (Anticipated) | Interventional | 2022-03-01 | Recruiting | |||
| Multicentric, Single Blind, Randomized Controlled Trial on Enteral Sedation Versus Intravenous Sedation in Critically Ill High-risk ICU Patients[NCT01360346] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-01-31 | Recruiting | ||
| Tailored Patient Management Guided With Absolute Cerebral Oximetry to Prevent Neurocognitive Injury in Elderly Patients Undergoing Cardiac Surgery.[NCT00991328] | Phase 3 | 15 participants (Actual) | Interventional | 2009-09-30 | Terminated (stopped due to low enrollment) | ||
| Non-Invasive Brain Stimulation and Delirium[NCT03518996] | 0 participants (Actual) | Interventional | 2018-09-01 | Withdrawn (stopped due to No Participants Enrolled) | |||
| HALO Trial: Haloperidol vs Olanzapine in Hyperactive Delirium in Palliative Care Patients; A Multi-Centre, Randomised-Controlled Trial[NCT04833023] | Phase 3 | 72 participants (Anticipated) | Interventional | 2022-05-18 | Recruiting | ||
| Continuous Cerebral Autoregulation Monitoring to Reduce Brain Injury From Cardiac Surgery[NCT00981474] | 460 participants (Actual) | Interventional | 2009-09-01 | Completed | |||
| Dexmedetomidine and IV Acetaminophen for the Prevention of Postoperative Delirium Following Cardiac Surgery in Adult Patients 60 Years of Age and Older[NCT02546765] | Phase 4 | 140 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Effects of Two Different Anesthesia-analgesia Methods on the Incidence of Postoperative Delirium: a Multicenter, Randomized Controlled Trial[NCT01661907] | 1,800 participants (Actual) | Interventional | 2011-11-21 | Completed | |||
| Prevention of Delirium in Inpatients Utilizing Melatonin[NCT02654314] | Phase 3 | 277 participants (Actual) | Interventional | 2016-07-31 | Terminated (stopped due to Lack of resources to complete the study. Descriptive statistics for the outcome measures collected are provided.) | ||
| Cukurova University Faculty of Medicine[NCT02360982] | 120 participants (Actual) | Observational | 2012-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Delirium will be assessed by the Confusion Assessment Method Instrument (CAM), a validated method of assessing delirium based on the presence of both (1) an acute onset of signs and symptoms with a fluctuating course AND (2) inattention; PLUS (3) disorganized thinking OR (4) an altered level of consciousness. (NCT02190903)
Timeframe: Up to 5 days post hip fracture surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| General Endotracheal Anesthesia | 2 |
| Regional (Spinal) Anesthesia | 0 |
Subject developed acute kidney injury within 7 days after surgical procedure. Based on Kidney disease: Improving Global Outcomes (KDIGO) classification system. (NCT00981474)
Timeframe: 7 days after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 56 |
| Intervention | 62 |
The composite neurological outcome was composed of clinical stroke, or new ischemic lesions detected on postoperative brain diffusion weighted magnetic resonance imaging(DWI), or cognitive decline from baseline to 4-6 weeks after surgery. (NCT00981474)
Timeframe: Up to 6 weeks post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care Group (Control) | 79 |
| Autoregulation Group | 70 |
Procedural insertion of intra-aortic balloon pump within 7 days after surgical procedure (NCT00981474)
Timeframe: 7 days after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 19 |
| Intervention | 14 |
Subjects need for mechanical lung ventilation more than 24 hours after planned surgical procedure. (NCT00981474)
Timeframe: Up to 28 days after surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 22 |
| Intervention | 13 |
Subject death within 28 days after surgical procedure (NCT00981474)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 12 |
| Intervention | 5 |
Use of multiple inotropic drugs greater than 24 hours after the planned surgical procedure until discharge from the hospital. (NCT00981474)
Timeframe: 7 days after surgery
| Intervention | participants (Number) |
|---|---|
| Usual Care Group (Control) | 13 |
| Autoregulation Group | 6 |
Subject diagnosis of multisystem organ failure after surgery. (NCT00981474)
Timeframe: Up to 28 days after surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 7 |
| Intervention | 2 |
Subjects requiring new renal replacement therapy prior to discharge from hospital (NCT00981474)
Timeframe: Up to 28 days after surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 6 |
| Intervention | 4 |
Clinical diagnosis of postoperative atrial fibrillation from date of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 89 |
| Intervention | 79 |
Assessed with Confusion Assessment Method or Confusion Assessment Method-ICU along with adjudication by team of experts (NCT00981474)
Timeframe: Postoperative days 1-4
| Intervention | Participants (Count of Participants) |
|---|---|
| Usual Care Group (Control) | 34 |
| Autoregulation Group | 19 |
Clinical diagnosis of sepsis from time of surgical procedure to discharge from the hospital. (NCT00981474)
Timeframe: Up to 28 days after surgery.
| Intervention | Participants (Count of Participants) |
|---|---|
| Control | 7 |
| Intervention | 2 |
Duration of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. Additional measurements will be made at 1 month and 1 year after discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM). (NCT02546765)
Timeframe: Participants will be followed for the duration of the hospital stay, an average of 6 days, and at 1 month and 1- year following the date of surgery
| Intervention | days (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 1 |
| Acetaminophen and Propofol | 1 |
| Placebo and Dexmedetomidine | 1 |
| Placebo and Propofol | 3 |
The follow up incidence of cognitive dysfunction will be analyzed at 1 month after discharge. T-MoCA is Telephone Montreal Cognitive Assessment Scale (MOCA). The T-MoCA is scored out of 22. The minimum score is 0 (worst) and maximum score is 22 (best). T-MOCA is converted back to 30 (full MOCA) with the help of conversion algorithms to a full MOCA.Example: 19/22 converts back to 30 by performing the following equation: (19×30) ÷ 22. The total converted score is 25.9 or 26/30 which is considered in the normal range. (NCT02546765)
Timeframe: Patients will be assessed for cognitive dysfunction with T-MOCA at 1 month following the date of surgery
| Intervention | units on a scale (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 17 |
| Acetaminophen and Propofol | 18 |
| Placebo and Dexmedetomidine | 19 |
| Placebo and Propofol | 18 |
Defined by the number of days admitted in the hospital following the completion of surgery. (NCT02546765)
Timeframe: Measured in days admitted in the hospital, an average of 6 days
| Intervention | days (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 8 |
| Acetaminophen and Propofol | 8 |
| Placebo and Dexmedetomidine | 9 |
| Placebo and Propofol | 8 |
Defined by the number of days admitted in the ICU prior to transfer to the general cardiac surgical floor (NCT02546765)
Timeframe: Measured in days admitted in the ICU, an average of 2 days
| Intervention | hours (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 28.8 |
| Acetaminophen and Propofol | 30.3 |
| Placebo and Dexmedetomidine | 49.1 |
| Placebo and Propofol | 29.3 |
Incidence of delirium will be analyzed between patients treated with and without IV acetaminophen, measured from 24 hours post-operation and daily until discharge. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method (CAM). (NCT02546765)
Timeframe: Participants will be followed for the duration of the hospital stay, an average of 5 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Acetaminophen and Dexmedetomidine | 2 |
| Acetaminophen and Propofol | 4 |
| Placebo and Dexmedetomidine | 8 |
| Placebo and Propofol | 9 |
MoCA scores at discharge will be reported in order to assess the occurrence of postoperative cognitive decline. Blinded study staff trained in administering the assessments will collect the data. MoCA is scored on a scale from 0 [worst] to 30 [best]; ǂA MoCA score of 24 would be equivalent to an Mini-Mental State Examination (MMSE) of about 27 or 28. Depending on education and peak intellectual attainment, such a score could be consistent with being either cognitively normal, or having very early mild cognitive impairment. Certainly such a person would be capable of living independently in the community and managing most or all of their affairs. (NCT02546765)
Timeframe: On the day of discharge, an average of 6 days
| Intervention | score on a scale (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 23 |
| Acetaminophen and Propofol | 24 |
| Placebo and Dexmedetomidine | 24 |
| Placebo and Propofol | 23 |
Defined by the amount of additional opioid (IV morphine or hydromorphone) and oral acetaminophen medications required in the first 48 hours postoperatively. Values will be converted to morphine equivalents for analysis. Total morphine equivalent is calculated as the sum of (fentanyl dose x 100)+(hydromorphone dose x 4)+morphine dose+(oxycodone dose x 1.5) (NCT02546765)
Timeframe: Participants will be followed for the first 48 hours postoperatively.
| Intervention | mcg (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 10050 |
| Acetaminophen and Propofol | 12611 |
| Placebo and Dexmedetomidine | 11382 |
| Placebo and Propofol | 12616 |
Severity of delirium will be analyzed, measured from 24 hours post-operation and daily until discharge. The worst severity experienced while in the hospital will be analyzed. Delirium will be defined as an acute change in pre-operative baseline condition with additional features of inattention and either disorganized thinking and altered loss of consciousness, as defined by the Confusion Assessment Method Severity Score (CAM-S, Confusion Assessment Method-Severity). range 0 [best/no delirium] to 19 [worst]; Minimal Clinical Important Difference (MCID) 2 points (NCT02546765)
Timeframe: Participants will be followed for the duration of the hospital stay, an average of 6 days
| Intervention | units on a scale (Median) |
|---|---|
| Acetaminophen and Dexmedetomidine | 10 |
| Acetaminophen and Propofol | 8 |
| Placebo and Dexmedetomidine | 6 |
| Placebo and Propofol | 9 |
Days utilizing restraints is defined as the number of days restraints were applied because of delirium in the first 14 days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | days (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
Delirium is defined by the Short Form Confusion Assessment Method (CAM). There must be inattention and either an acute or fluctuating course plus either disorganized thinking or an altered level of consciousness to be diagnosed with delirium. Presented is a count of individuals with reported delirium during hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Melatonin | 2 |
| Cellulose Microcrystylline | 8 |
Length of stay is defined as the total time hospitalized for the acute illness (in days). (NCT02654314)
Timeframe: from day of admission to completion of acute care, not to exceed 30 days
| Intervention | days (Mean) |
|---|---|
| Melatonin | 4.58 |
| Cellulose Microcrystylline | 4.71 |
Number of delirium anti-psychotic drug doses given for symptoms of delirium. Presented are the number of doses per days of hospitalization. (NCT02654314)
Timeframe: length of hospitalization, not to exceed 14 days
| Intervention | number of doses per days of hospitalizat (Median) |
|---|---|
| Melatonin | 0 |
| Cellulose Microcrystylline | 0 |
11 reviews available for trazodone and Dementia
| Article | Year |
|---|---|
Targeting the Unfolded Protein Response as a Disease-Modifying Pathway in Dementia.
Topics: Animals; Brain; Dementia; Humans; Trazodone; Unfolded Protein Response | 2022 |
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
Antidepressants for agitation and psychosis in dementia.
Topics: Adult; Antidepressive Agents; Citalopram; Dementia; Humans; Psychomotor Agitation; Psychotic Disorde | 2011 |
[Serotonin reuptake inhibitors in depression of Alzheimer's disease and other dementias].
Topics: Aged; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Clinical Tri | 2003 |
Trazodone for agitation in dementia.
Topics: Antidepressive Agents, Second-Generation; Dementia; Humans; Psychomotor Agitation; Selective Seroton | 2004 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
Delirium in older persons.
Topics: Aged; Anti-Anxiety Agents; Antipsychotic Agents; Delirium; Dementia; Diagnosis, Differential; Humans | 2006 |
[Frontotemporal dementia].
Topics: Adenosine Triphosphatases; Aged; Aged, 80 and over; Alzheimer Disease; Amyotrophic Lateral Sclerosis | 2007 |
Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.
Topics: Aged; Aggression; Antipsychotic Agents; Anxiety Disorders; Behavior Therapy; Buspirone; Carbamazepin | 1996 |
Treatment strategies for agitation and psychosis in dementia.
Topics: Aged; Anti-Anxiety Agents; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Clozapine; | 1996 |
Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia.
Topics: Adrenergic beta-Antagonists; Alzheimer Disease; Buspirone; Carbamazepine; Dementia; Humans; Lithium; | 1992 |
Management of the behavioral symptoms associated with dementia.
Topics: Aged; Aggression; Antipsychotic Agents; Dementia; Humans; Pindolol; Propranolol; Psychomotor Agitati | 1989 |
2 trials available for trazodone and Dementia
| Article | Year |
|---|---|
Frontotemporal dementia: a randomised, controlled trial with trazodone.
Topics: Adult; Aged; Aged, 80 and over; Cross-Over Studies; Dementia; Double-Blind Method; Female; Humans; M | 2004 |
A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Dementia; D | 1997 |
19 other studies available for trazodone and Dementia
| Article | Year |
|---|---|
Trazodone and patient outcomes in dementia-Limitations of naturalistic cohort data.
Topics: Antidepressive Agents; Cohort Studies; Dementia; Humans; Trazodone | 2022 |
Changes in the Initiation of Antipsychotics and Trazodone Over Time: A Cohort Study of New Admissions to Nursing Homes in Ontario, Canada.
Topics: Antipsychotic Agents; Cohort Studies; Dementia; Humans; Nursing Homes; Ontario; Retrospective Studie | 2023 |
[Pimavanserin and trazodone combination in behavioral disorders in severe dementia with Lewy bodies].
Topics: Clozapine; Dementia; Drug Inverse Agonism; Hallucinations; Humans; Lewy Body Disease; Trazodone | 2023 |
Clinical profile of trazodone users in a multisetting older population: data from the Italian GeroCovid Observational study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; COVID-19; Cross-Sectional Studies; Dementia; Female; | 2023 |
Antidepressant Use and Cognitive Outcomes in Very Old Women.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cognition; Cogniti | 2018 |
Evaluating the dose-dependent mechanism of action of trazodone by estimation of occupancies for different brain neurotransmitter targets.
Topics: Animals; Antidepressive Agents; Brain; Dementia; Depression; Depressive Disorder; Humans; Hypnotics | 2018 |
Psychotropic drugs for the behavioural and psychological symptoms of dementia: no free ride.
Topics: Aged; Dementia; Humans; Psychotropic Drugs; Retrospective Studies; Trazodone | 2018 |
Comparative risk of harm associated with trazodone or atypical antipsychotic use in older adults with dementia: a retrospective cohort study.
Topics: Accidental Falls; Aged; Aged, 80 and over; Antipsychotic Agents; Cohort Studies; Dementia; Fractures | 2018 |
Trazodone use and risk of dementia: A population-based cohort study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Cohort Studies; Dementia; Electro | 2019 |
Trazodone for the treatment of sleep disorders in dementia: an open-label, observational and review study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Dementia; Female; Humans; Hypnoti | 2011 |
Pharmacologic management by clinical pharmacists of behavioral and psychological symptoms of dementia in nursing home residents: results from a pilot study.
Topics: Aged; Aged, 80 and over; Dementia; Female; Geriatric Assessment; Health Services for the Aged; Homes | 2003 |
[Trazodone for the treatment of behavioral and psychological symptoms of dementia (BPSD) in Alzheimer's disease: a retrospective study focused on the aggression and negativism in caregiving situations].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Anti-Anxiety Age | 2006 |
Clinical and biological aspects of depression in the elderly.
Topics: Aged; Dementia; Depression; Doxepin; Humans; Imipramine; Methylphenidate; Middle Aged; Trazodone | 1980 |
Reversible intermittent rhythmic myoclonus with fluoxetine in presumed Pick's disease.
Topics: Affective Disorders, Psychotic; Brain; Dementia; Dose-Response Relationship, Drug; Electroencephalog | 1994 |
'The use of selective serotonin reuptake inhibitors for depression and psychosis complicating dementia'--1997, 12, 519-527.
Topics: Buspirone; Dementia; Depression; Drug Therapy, Combination; Humans; Psychotic Disorders; Selective S | 1998 |
Trazodone for symptoms of frontal lobe atrophy.
Topics: Adolescent; Aggression; Atrophy; Attention Deficit Disorder with Hyperactivity; Child; Dementia; Fet | 2000 |
Reply to Risse and Barnes: Pharmacologic treatment of agitation associated with dementia.
Topics: Dementia; Humans; Psychomotor Agitation; Trazodone | 1988 |
Trazodone in dementia.
Topics: Dementia; Female; Humans; Middle Aged; Trazodone | 1986 |
Consistent reversal of abnormal DSTs after different antidepressant therapies in a patient with dementia.
Topics: Amitriptyline; Antidepressive Agents; Dementia; Depressive Disorder; Dexamethasone; Humans; Hydrocor | 1985 |